Study on the effect of honey products on Parkinson's disease

Study on the effect of honey products on Parkinson's disease - Study on the effect of honey products on Parkinson's disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047517

Enrollment

Registered

2022-04-18

Start date

2020-10-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients diagnosed with Parkinson's disease by the British Brain Bank Clinical Criteria 2) Patients with H & Y classification 2-4 degrees 3) Patients aged between 20 and 85 at the time of consent 4) Patients who have been treated with levodopa for 6 months or more by the time consent is obtained and who have a wearing-off phenomenon 5) Patients receiving levodopa therapy at a fixed dosage and administration (3 times a day or more) from the start of observation 6) Patients who have been receiving a certain dosage and administration from the start of observation when using entacapone and opicapone together 7) Patients receiving a certain dosage and administration from 14 days before the start of observation when using a combination of dopamine agonist, amantadine, anticholinergic drug, droxidopa, istradefylline or zonisamide 8) Patients who have given written consent to participate in this study

Exclusion criteria

Exclusion criteria: 1) Patients with serious physical symptoms other than Parkinson's disease (cardiac / liver / renal dysfunction, hematopoietic disorders, etc.) 2) Viral hepatitis: HBsAg positive or HCV antibody positive 3) Women who are pregnant or may become pregnant 4) Patients with drug addiction / alcohol dependence 5) Patients with serious psychiatric symptoms (confusion, hallucinations, delusions, abnormal behavior, etc.) within 3 months before obtaining the consent form 6) In addition, when the principal investigator or the research coordinator judges that participation in this research is not appropriate.

Design outcomes

Primary

Measure	Time frame
Average daily off-time changes from baseline (7-day pre-evaluation mean during treatment-baseline 7-day pre-evaluation mean)	—

Secondary

Measure	Time frame
Average daily off-time (average value for 7 days before each evaluation), UPDRS part II total score, UPDRS part III total score, PDQ-39summary Index and domain score	—

Countries

Japan

Contacts

Public ContactTAKUYUKI ENDO

Osaka Toneyama Medical Center Neurology

endo.takuyuki.gr@mail.hosp.go.jp09052438859

Outcome results